• Cefazedone (Refosporen): Applied Research Workflows

  2026-09-04

  Cefazedone (Refosporen) supports practical susceptibility testing, β-lactamase-focused experiments, and translational pharmacokinetic workflows. This guide connects broth dilution design with a validated UFLC–MS/MS method for measuring cefazedone alongside etimicin in plasma.

• circHIF1A Axis Drives M2 Polarization in LUAD

  2026-09-04

  The reference study identifies a circHIF1A/miR-486-5p/GRHL2 competing endogenous RNA axis that links malignant lung adenocarcinoma behavior with macrophage M2 polarization. Patient samples, LUAD cell models, and xenografts indicate that this pathway promotes tumor growth while remodeling the immune microenvironment through IL-10-associated signaling.

• TCAIM–OGDH Control of Mitochondrial Metabolism

  2026-09-03

  A 2025 Molecular Cell study identifies TCAIM as a mitochondrial DNAJC co-chaperone that selectively binds native OGDH and promotes its reduction through HSPA9 and LONP1. This work establishes mitochondrial proteostasis as a post-translational regulator of OGDH complex activity, carbohydrate catabolism, and broader metabolic state.

• ONX-0914: Reading Immunoproteasome Biology

  2026-09-02

  ONX-0914 and PR-957 provide a selective way to interrogate LMP7-dependent immune signaling. This article connects cytokine production blockade and autoimmune models with a seminal study showing how immunoproteasome activity can reshape antiviral restriction and experimental design.

• Spatial Lipid Changes in Postoperative Cognitive Dysfunction

  2026-09-02

  This 2024 study combines spatial metabolomics, behavioral testing, immunofluorescence, and electron microscopy to identify hippocampal lipid remodeling associated with postoperative cognitive dysfunction after cardiopulmonary bypass. Its intervention data implicate reduced iPLA2 activity and increased serine palmitoyltransferase signaling as potentially modifiable features, while highlighting the value of region-resolved lipid analysis in neurocognitive research.

• Persistent rDNA Damage and PML-Nucleolar Compartments

  2026-09-01

  Urbancokova, Hornofova, and colleagues show that topological stress and RNA polymerase I inhibition generate persistent lesions in ribosomal DNA that drive PML-nucleolar associations. By combining genotoxic-stress screening with targeted I-PpoI cleavage and repair-pathway perturbation, the study links unresolved rDNA damage to nucleolar reorganization and cellular senescence.

• CCK-8 for Translational Cancer Research

  2026-09-01

  Discover how Cell Counting Kit-8 (CCK-8) can connect metabolic viability measurements with translational cancer research. This article presents a rigorous framework for interpreting WST-8 data in antibody-drug conjugate and immunotherapy studies, while clarifying assay limits and experimental design choices.

• Protease Inhibitor Cocktail for Plant Signaling

  2026-08-31

  Discover how a Protease Inhibitor Cocktail can preserve transient plant signaling proteins and phosphorylation states during symbiosis research. This workflow-centered guide connects plant cell protein stability with assay design, using the NSP2–MYB40 discovery as a practical case study.

• Spirocyclic POM Analogues Target MmpL3 in TB

  2026-08-31

  The reference study develops spirocyclic phenyl oxazole methyl analogues and identifies compound 5c as a potent inhibitor of Mycobacterium tuberculosis, including drug-resistant clinical isolates. Genetic resistance analysis, molecular docking, ADME and pharmacokinetic profiling, and THP-1 cytotoxicity testing support MmpL3 as a mechanistic target and establish a useful starting point for anti-tubercular drug discovery.

• STING Agonist-1 and B Cell Immunity

  2026-08-30

  A translational framework for using STING agonist-1 to investigate the relationship between innate immune signaling, CD40–TRAF2 biology, IRF4-driven B cell activation, and tertiary lymphoid structures in cancer research.

• Deep Learning for iPSC-CM Cardiotoxicity Screening

  2026-08-29

  Grafton and colleagues combined high-content imaging, induced pluripotent stem cell-derived cardiomyocytes, and deep learning to identify cardiotoxic phenotypes across chemically diverse compounds. The resulting single-parameter score provides a scalable early-screening strategy, while the study also shows why computational prioritization should be followed by orthogonal mechanistic validation.

• Entinostat: From HDAC Target to Assay Insight

  2026-08-28

  Entinostat (MS-275) is a selective class I HDAC inhibitor whose value depends on linking target engagement to time-, tissue-, and phenotype-specific outcomes. This article uses axolotl regeneration research to develop a more rigorous framework for cancer cell proliferation inhibition, retinoblastoma treatment research, and translational assay design.

• Cytochalasin B: Actin Assay Workflows

  2026-08-28

  Cytochalasin B is a reversible, cell-permeable probe for separating actin-dependent effects on migration, uptake, and cytokinesis from broader loss of cell fitness. This workflow-centered guide combines dose finding, washout controls, orthogonal viability readouts, and lessons from integrated genotoxicity testing to improve reproducibility in cytoskeletal assays.

• Cefazedone PK/PD: From MIC to Clinical Design

  2026-08-27

  Cefazedone (Refosporen) is examined through an exposure-aware framework that connects MIC testing, protein binding, and time-dependent pharmacodynamics. This guide translates clinical PK/PD evidence into practical assay and translational study decisions.

• Hydroxytyrosol: From Redox Signal to Assay Design

  2026-08-27

  Hydroxytyrosol is an olive-derived antioxidant bioactive compound with value in oxidative stress modulation and cardiovascular health research. This article translates comparative polyphenol findings into a rigorous framework for selecting cellular models, paired readouts, controls, and interpretation strategies.

8067 records 1/538 page Next 12345 下5页 Last page